EMA Recommends Granting a Marketing Authorisation for Lurbinectedin By Ogkologos - April 30, 2026 149 0 Facebook Twitter Google+ Pinterest WhatsApp It is indicated for the maintenance treatment of adult patients with extensive-stage small cell lung cancer Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR Man Gives Up His First-Class Seat For 88-Year-Old Woman, Makes Her... November 16, 2021 Longer Duration of Treatment with ICIs Associated with a Higher Rate... March 5, 2025 Olivia Newton-John Shares Positive News On Breast Cancer: “I’m Winning Over... January 28, 2020 Ovarian Cancer Studies Aim to Reduce Racial Disparities, Improve Outcomes July 16, 2020 Load more HOT NEWS Biomarker Analyses in Patients with HER2-positive or HER2-low Gastric and Gastro-oesophageal... FDA Grants Accelerated Approval to Repotrectinib for Adult and Paediatric Patients... ΟΡΘΟΚΟΛΙΚΟΣ ΚΑΡΚΙΝΟΣ Mom Who Lost Child Donates Breast Milk To Mom With Cancer
